A single injection was sufficient to maintain therapeutic drug levels and protect mice from hyperglycemia and weight gain for >7 days, demonstrating the suitability of a GLP1-ELP-FGF21 depot for a once-weekly dosing scheme. The gene discussed is GLP1R; the disease is Hyperglycemia.